However, PD-L1 is generally considered to be up-regulated in ALK-positive lung cancer and is not related to treatment efficacy.[11,12,18,19] ALK-positive lung cancer patients who responded to ICIs were older, had a history of smoking, and had shorter PFS for initial ALK-TKI. The gene discussed is ALK; the disease is lung cancer.